Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis

NCT02121210 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02121210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02121210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2014
Completion date
May 31, 2015
Enrollment
132 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis